Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism

Free Radical Biology and Medicine

Volumn 46, Issue 2, 2009, Pages 232-237

  Mattson, David M ^a   Ahmad, Iman M ^b   Dayal, Disha ^c   Parsons, Arlene D ^c   Aykin Burns, Nukhet ^c   Li, Ling ^c   Orcutt, Kevin P ^c   Spitz, Douglas R ^c   Dornfeld, Kenneth J ^d   Simons, Andrean L ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b HASHEMITE UNIVERSITY   (Jordan)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d UNIVERSITY OF MINNESOTA DULUTH   (United States)

Author keywords

Azidothymidine; BSO; Cancer; Cisplatin; Free radicals; Mitochondrial membrane potential; NAC; Oxidative stress

Indexed keywords

1 BUTHIONINE SULFOXIMINE; ACETYLCYSTEINE; BUTHIONINE SULFOXIMINE; CISPLATIN; GLUTATHIONE; GLUTATHIONE DISULFIDE; THIOL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; GLUTATHIONE METABOLISM; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; SENSITIZATION;

ACETYLCYSTEINE; BUTHIONINE SULFOXIMINE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG THERAPY, COMBINATION; GLUTATHIONE; HEAD AND NECK NEOPLASMS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; OXIDATIVE STRESS; SULFHYDRYL COMPOUNDS; ZIDOVUDINE;

EID: 58049100967     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2008.10.023     Document Type: Article

References (46)

1. Oberley L.W., and Buettner G.R. Role of superoxide dismutase in cancer: a review. Cancer Res. 39 (1979) 1141-1149
2. Konstantinov A.A., Peskin A.V., Popova E., Khomutov G.B., and Ruuge E.K. Superoxide generation by the respiratory chain of tumor mitochondria. Biochim. Biophys. Acta 894 (1987) 1-10
3. Szatrowski T.P., and Nathan C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51 (1991) 794-798
4. Toyokuni S., Okamoto K., Yodoi J., and Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 358 (1995) 1-3
5. Spitz D.R., Sim J.E., Ridnour L.A., Galoforo S.S., and Lee Y.J. Glucose deprivation-induced oxidative stress in human tumor cells: a fundamental defect in metabolism?. Ann. N. Y. Acad. Sci. 899 (2000) 349-362
6. Copeland W.C., Wachsman J.T., Johnson F.M., and Penta J.S. Mitochondrial DNA alterations in cancer. Cancer Invest. 20 (2002) 557-569
7. Carew J.S., and Huang P. Mitochondrial defects in cancer. Mol. Cancer 1 (2002) 1-9
8. Hlavata L., Aguilaniu H., Pichova A., and Nystrom T. The oncogenic RAS2 (val19) mutation locks respiration independently of PKA in a mode prone to generate ROS. EMBO J. 22 (2003) 3337-3345
9. Richter C., Gogvadze V., Laffranchi R., Schlapbach R., Schweizer M., Suter M., Walter P., and Yaffee M. Oxidants in mitochondria: from physiology to diseases. Biochim. Biophys. Acta 1271 (1995) 67-74
10. Jackson A.L., and Loeb L.A. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat. Res. 477 (2001) 7-21
11. Vafa O., Wade M., Kern S., Beeche M., Pandita T.K., Hampton G.M., and Wahl G.M. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene induced genetic instability. Mol. Cell 9 (2002) 1031-1044
12. Meijer C., van Luyn M.J., Nienhuis E.F., Blom N., Mulder N.H., and de Vries E.G. Ultrastructural morphology and localization of cisplatin-induced platinum-DNA adducts in a cisplatin-sensitive and -resistant human small cell lung cancer cell line using electron microscopy. Biochem. Pharmacol. 61 (2001) 573-578
13. Spitz D.R., Phillips J.W., Adams D.T., Sherman C.M., Deen D.F., and Li G.C. Cellular resistance to oxidative stress is accompanied by resistance to cisplatin: the significance of increased catalase activity and total glutathione in hydrogen peroxide-resistant fibroblasts. J. Cell Physiol. 156 (1993) 72-79
14. Mitchell J.B., and Russo A. The role of glutathione in radiation and drug induced cytotoxicity. Br. J. Cancer Suppl. 8 (1987) 96-104
15. Lewis W., Copeland W.C., and Day B.J. Mitochondrial DNA depletion, oxidative stress and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab. Invest. 81 (2001) 777-789
16. Lund K.C., and Wallace K.B. Adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors. Toxicol. Appl. Pharmacol. 226 (2008) 94-106
17. Anderson M.E. Handbook of Methods for Oxygen Radical Research (1985), CRC Press, Boca Raton, FL 317-323
18. Griffith O.W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem. 106 (1980) 207-212
19. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
20. 2-resistant cell lines: do aldehydic by-products of lipid peroxidation contribute to oxidative stress?. Biochem. J. 267 (1990) 453-459
21. Browne M.J., Beitz J., Clark J.W., Cummings F.J., Weitberg A., Murray C., and Darnowski J.W. A phase I study of zidovudine (AZT) combined with methotrexate in patients with advanced cancer. Proc. ASCO 12 (1993) A451 [Abstract]
22. Sunderman Jr. F.W., Sporn J., Hopfer S.M., Sweeney K.R., Chakraborty N.G., and Greenberg B. Platinum in blood mononuclear cells from patients after cisplatin therapy. Ann. Clin. Lab. Sci. 20 (1990) 379-384
23. Schafer F.Q., and Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30 (2001) 1191-1212
24. Kroemer G., and Reed J.C. Mitochondrial control of cell death. Nat. Med. 6 (2000) 513-519
25. Brown G.C., and Borutaite V. Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free Radic. Biol. Med. 33 (2002) 1440
26. Forastiere A.A. Overview of platinum chemotherapy in head and neck cancer. Semin. Oncol. 21 (1994) 20-27
27. Yang Z., Schumaker L.M., Egorin M.J., Zuhowski E.G., Guo Z., and Cullen K.J. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin. Cancer Res. 12 (2006) 5817-5825
28. Jing X.B., Cai X.B., Hu H., Chen S.Z., Chen B.M., and Cai J.Y. Reactive oxygen species and mitochondrial membrane potential are modulated during CDDP-induced apoptosis in EC-109 cells. Biochem. Cell Biol. 85 (2007) 265-271
29. Mitsuya H., Weinhold K., Furman P., St Clair M., Lehrman S., Gallo R., Bolognesi D., and Barry D. Broder, S. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82 (1985) 7096-7100
30. Yarchoan R., Klecker R., Weinhold K., Markham P., Lyerly H., Durack D., Gelmann E., Lehrman S., Blum R., and Barry D. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1 (1986) 575-580
31. Lewis W., Gonzalez B., Chomyn A., and Papoian T. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J. Clin. Invest. 89 (1992) 1354-1360
32. Lewis W., and Dalakas M.C. Mitochondrial toxicity of antiviral drugs. Nat. Med. 1 (1995) 417-422
33. Collins M., Sondel N., Cesa D., and Hellerstein M. Effect of nucleoside reverse transcriptase inhibitors on mitochondrial DNA synthesis in rats and humans. J. Acquired Immune Defic. Syndr. 37 (2004) 1132-1139
34. Wagner C.R., Ballato G., Akanni A.O., McIntee E.J., Larson R.S., Chang S., and Abul-Hajj Y.J. Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors. Cancer Res. 57 (1997) 2341-2345
35. Melana S.M., Holland J.F., and Pogo B.G. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin. Cancer Res. 4 (1998) 693-696
36. Burgunder J.M., Varriale A., and Lauterburg B.H. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur. J. Clin. Pharmacol. 36 (1989) 127-131
37. Spitz D.R., Kinter M.T., and Roberts R.J. The contribution of increased glutathione content to mechanisms of oxidative stress resistance in hydrogen peroxide resistant hamster fibroblasts. J. Cell Physiol. 165 (1995) 600-609
38. Arrick B.A., Griffith O.W., and Cerami A. Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis. J. Exp. Med. 153 (1981) 720-725
39. Andringa K.K., Coleman M.C., Aykin-Burns N., Hitchler M.J., Walsh S.A., Domann F.E., and Spitz D.R. Inhibition of glutamate cysteine ligase (GCL) activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-d-glucose. Cancer Res. 66 (2006) 1605-1610
40. Simons A.L., Ahmad I.M., Mattson D.M., Dornfeld K.J., and Spitz D.R. 2-Deoxy-d-glucose (2DG) combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 67 (2007) 3364-7330
41. Bailey H.H. l-S,R-Buthionine sulfoximine: historical development and clinical issues. Chem. Biol. Interact. 111 (1998) 39-54
42. Scanlon K.J., Funato T., Pezeshki B., Tone T., and Sowers L.C. Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cells. Cancer Commun. 2 (1990) 339-343
43. Savaraj N., Wu C., Wangpaichitr M., Kuo M.T., Lampidis T., Robles C., Furst A.J., and Feun L. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int. J. Oncol. 23 (2003) 173-179
44. Stewart D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 63 (2007) 12-31
45. Morgan Jr. R.J., Newman E.M., Sowers L., Scanlon K., Harrison J., Akman S., Leong L., Margolin K., Niland J., Raschko J., Somlo G., Carroll M., Chow W., Tetef M., Hamasaki V., Yen Y., and Doroshow J.H. Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies. Cancer Chemother. Pharmacol. 51 (2003) 459-464
46. Bailey H.H., Ripple G., Tutsch K.D., Arzoomanian R.Z., Alberti D., Feierabend C., Mahvi D., Schink J., Pomplun M., Mulcahy R.T., and Wilding G. Phase I study of continuous-infusion l-S,R-buthionine sulfoximine with intravenous melphalan. J. Natl. Cancer Inst. 89 (1997) 1789-1796